Newsroom
Encouraging Results With Vaccine Against Pancreatic Cancer Developed at CINJ
'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.
Repeal of Employer Mandate Could Shake Up Group Insurance
Amid strong lobbying by business groups, support is growing to end the Affordable Care Act's employer mandate, a change that would see millions more Americans buying their health insurance through exchanges.
Lung Cancer Screening could Cost Medicare Billions
A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.
Cigna Plows Ahead with Quality-Based Reimbursement Venture
As part of a contract extension with Tenet Healthcare, Cigna has established a first of its kind quality-based reimbursement agreement.
Cost Prevents Approval of Revlimid in the UK...Again
NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.
Clovis Oncology's Treatment for EGFR-mutant (T790M) NSCLC Patients Receives Breakthrough Designation
CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.
Myriad's Prolaris Diagnostic Kit Holds Value in Prostate Cancer Prognosis
Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.
Geneticists on Both Coasts Issue 'Call to Action' On Need to Share DNA Data
In the new issue of Evidence-Based Oncology, Ellen T. Matloff, MS, CGC, and Rachel E. Barnett, MS, CGC, of the Yale Cancer Center and Robert Nussbaum, MD, of UC San Francisco write that efforts by some genetic testing laboratories to grab market share in the lucrative BRCA testing market may put patients at risk, while violating ethical standards issued by the American Medical Association.
2013 Volume 19 Number SP11
Bundled Payments Could Cut Medicare Fraud, Experts Say
Health and policy experts are pushing for a system that pays doctors a lump sum for medical care or allows them to share in savings, saying it will save millions of dollars over current fee-for-service payments that can lead to fraud and over-use of medications.
Higher Health Insurance Cost-Sharing Impacts Asthma Care for Low-Iincome Kids
Parents in low-income families were less likely to delay asthma care for their children or avoid taking their children to see a doctor is they had lower vs. higher levels of health insurance cost-sharing.
Encouraging Results With Radioimmunotherapy and Gemcitabine Treatment in Metastatic PDAC
Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.
Arzerra Fails in Phase 3 Trial for B-cell Lymphoma
GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.
States Stick to Insurance Exchange Models
Few states could claim Obamacare's first enrollment period was smooth-whatever the final numbers-but most will approach their insurance exchanges the same way for the 2015 window. None has asked the Obama administration to take over its marketplace or elected to abandon HealthCare.gov in favor of running its own.
Takeda Unveils Phase 3 ELM-PC4 Trial Data in Men With Chemotherapy-Naive mCRPC
Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.
CMS Issues Final Rule on Navigators, Risk Corridors for 2015
The CMS on Friday issued its final rule for exchange and insurance market standards for 2015 and beyond, a potpourri of policies that address consumer notices, quality reporting and enrollee satisfaction surveys, the Small Business Health Options Program (SHOP), standards for navigators and other consumer assisters, and policies regarding the premium stabilization programs, among others.
Poorer Health of Surgery Patients on Medicaid May Alter Law's Bottom Line
Surgery patients covered by Medicaid arrive at the hospital in worse health, experience more complications, stay longer and cost more than patients with private insurance, a new study has found.
Oral Bacterial Profile in the Diagnosis of Pancreatic Cancer
Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.
Pfizer to File Early NDA for it's Breast Cancer Drug Palbociclib
Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.
N-of-One To Collaborate With OncoDNA to Provide Personalized Cancer Therapy
A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.
Nivolumab Gets Breakthrough Designation for Hodgkin's Lymphoma
BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.
3 Ways to Create Value-Oriented Healthcare
Focus on services' worth to combat soaring healthcare spending.
New Payment Models Could Motivate Providers to Cut Wasteful Services
The overuse of pricey medical technology and medication presents a complex challenge for policymakers, hospitals and doctors trying to reduce costs.
Necitumumab by Eli Lilly Improves OS in a Phase 3, First-Line Treatment of NSCLC
Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).
Lung Cancer Screening Could Cost Medicare Billions
Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.
For Medicaid Patients, Access To Primary-Care May Not Be As Advertised
Using mystery shoppers looking for access to health care, Public Health Seattle & King County has found troubling indications that access to primary-care providers may not be as advertised.